PIRSPIERIS PHARMACEUTICALS, INC.

Nasdaq pieris.com


$ 16.77 $ 0.34 (2.07 %)    

Wednesday, 14-Aug-2024 15:45:01 EDT
QQQ $ 463.74 $ 0.15 (0.03 %)
DIA $ 400.12 $ 2.30 (0.58 %)
SPY $ 543.85 $ 1.71 (0.32 %)
TLT $ 97.88 $ 0.61 (0.63 %)
GLD $ 226.19 $ -1.86 (-0.82 %)
$ 16.75
$ 16.09 x 250
-- x --
-- - --
$ 6.20 - $ 41.78
44,575
na
21.76M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-04-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-02-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-13-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-15-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-30-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-23-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-30-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 palvella-therapeutics-and-pieris-pharmaceuticals-to-merge-creating-a-nasdaq-listed-entity-with-805m-cash-to-drive-development-of-novel-skin-disease-therapies

Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing...

 pieris-pharmaceuticals-announces-1-for-80-reverse-stock-split

https://www.sec.gov/Archives/edgar/data/1583648/000143774924012442/ex_655549.htm

 why-galecto-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket

Gainers

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION